| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
